Recent EQ News
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 12:00:00 PM
- Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis • Business Wire • 04/01/2024 12:00:00 PM
- Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights • Business Wire • 03/25/2024 08:01:00 PM
- Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference • Business Wire • 03/22/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:35:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:01:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:12:11 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 10:09:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:08:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:17:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:14:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:12:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 01:05:52 PM
- Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease • Business Wire • 12/21/2023 01:00:00 PM
- EQ Bank Card launches in Québec as Carte Banque EQ • PR Newswire (Canada) • 11/20/2023 04:23:00 PM
- EQ Bank Card launches in Québec as Carte Banque EQ • PR Newswire (US) • 11/20/2023 04:23:00 PM
- Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology • Business Wire • 11/13/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:10:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:05:10 PM
- Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates • Business Wire • 11/08/2023 09:01:00 PM
- Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology • Business Wire • 11/06/2023 01:00:00 PM
- Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology • Business Wire • 10/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 12:05:52 PM
- Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium • Business Wire • 10/16/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 09:28:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM